Pivotal clinical studies presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showed promising findings that could benefit patients with early-stage resectable non-small cell lung cancer (NSCLC).
Eric Singhi, MD, MD Anderson Cancer Center, Houston, Texas, showcased the CheckMate 816 and NeoADAURA trials while speaking with Mitchell Alexander Parma, MD, also of MD Anderson Cancer Center.
He discussed potential clinical implications of the CheckMate 816 study that showed a significant overall survival (OS) benefit in updated findings presented at ASCO. Neoadjuvant nivolumab plus chemotherapy demonstrated a 5-year OS rate of 65% compared with 55% with chemotherapy alone.
Furthermore, Dr. Singhi shared his excitement about the NeoADAURA study that evaluated neoadjuvant osimertinib in combination with chemotherapy versus chemotherapy alone in patients with resectable EGFR-mutated NSCLC. Patients in the study were randomized 1:1:1 to either receive the combination, osimertinib alone, or chemotherapy alone. At ASCO, the researchers presented data which showed that osimertinib significantly improved major pathological response (MPR)—the study’s primary endpoint—compared with chemotherapy. In the osimertinib plus chemotherapy and osimertinib monotherapy arms, the MPR rate was 26% and 25%, respectively, versus an MPR rate of 2% in the chemotherapy alone arm.
